Rakuten Medical Closes Deal with Merck KGaA, Darmstadt, Germany

Rakuten Medical announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA, Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program. Rakuten Medical uses cetuximab in an intermediate form as the antibody component in its product candidate ASP-1929, an investigational antibody-dye conjugate being studied for the treatment of recurrent, locoregional head and neck cancers. Under this agreement, Rakuten Medical may use cetuximab to produce ASP-1929 for clinical trials and commercial sales.

Earlier this year at the World Economic Forum in Davos, Rakuten Medical and Merck KGaA, Darmstadt, Germany memorialized their intent to join forces to explore ways to help patients conquer cancer.

"Rakuten Medical is excited to partner with Merck KGaA, Darmstadt, Germany, a leading science and technology company," said Hiroshi Mikitani, Chairman and CEO of Rakuten Medical. "Rakuten Medical is committed to partnering with world class companies such as Merck KGaA, Darmstadt, Germany in order to carry forward its mission to conquer cancer."

Rakuten Medical's ASP-1929 combines cetuximab and a light activatable dye, IRDye® 700DX. Cetuximab, a monoclonal antibody, targets and binds specifically to the epidermal growth factor receptors (EGFR), which are overexpressed in several cancers. After binding to EGFR-expressing cancer cells, ASP-1929 is locally activated by non-thermal red light (690 nm) illumination emitted by an investigational laser device system.  Pre-clinical data indicate that illumination of ASP-1929 induces a biophysical process that compromises cell membrane integrity, leading to cancer cell death and tumor necrosis.